Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Files NDA for Intestinal Amebiasis Treatment Paromomycin in Japan
December 26, 2011
- Novo Nordisk Pharma Submits NDA for Insulin Degludec
December 26, 2011
- Takeda to Set Up New Unit to Support Investigator-Initiated Research
December 22, 2011
- BMKK, Pfizer Japan Apply for Apixaban for SPAF in Japan
December 22, 2011
- Takeda to Acquire Intellikine to Enhance Oncology Pipeline
December 22, 2011
- Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
- Daiichi Sankyo Grants Marketing Rights for Cravit to Ranbaxy in Malaysia
December 22, 2011
- Rohto’s Mentholatum Medi-Quick H on Track to Become Hit Product in 1st Year
December 22, 2011
- Nexium Takes No. 1 and No. 2 Position in HP Market: RepTrack Survey
December 21, 2011
- MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
- Chugai to Establish Pool System of Candidate Leaders
December 20, 2011
- Meiji Seika Pharma Licenses Udenafil from Dong-A Pharmaceutical
December 20, 2011
- GSK Applies for Add’l Indication for Botox for Axillary Hyperhidrosis
December 20, 2011
- SMBC Nikko Securities Includes Astellas Pharma in 20 Stocks to Watch in 2012
December 19, 2011
- Takeda Decides not to Commercialize Peginesatide in Japan
December 19, 2011
- Valeant Announces Successful Results from PIII Onychomycosis Study of Efinaconazole
December 19, 2011
- Pfizer Tops Doctor Survey Rankings for Pharmaceutical Company Website Access
December 16, 2011
- Chugai to Set Up Company in Singapore Targeting Antibody Drug Discovery
December 16, 2011
- Sanofi-aventis Appeals to IP High Court Claiming Allegra’s Use Patents
December 16, 2011
- Eisai Receives Approval for Halaven in Canada
December 16, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…